                                                                                                                   
                                                   UNITED STATES                                                   
                                                                                                                   
                                                                                                                   
                                        SECURITIES AND EXCHANGE COMMISSION                                         
                                                                                                                   
                                                                                                                   
                                               WASHINGTON, DC 20549                                                
                                                                                                                   
                                                                                                                   
                                                     FORM 8-K                                                      
                                                                                                                   
                                                  CURRENT REPORT                                                   
                                                                                                                   
                                      Pursuant to Section 13 or 15(d) of The                                       
                                                                                                                   
                                          Securities Exchange Act of 1934                                          
                                                                                                                   
                                 Date of report (Date of earliest event reported):                                 
                                                                                                                   
                                                  April 22, 2021                                                   
                                                                                                                   
                                                 Johnson & Johnson                                                 
                                                                                                                   
                              (Exact name of registrant as specified in its charter)                               
                                                                                                  
  New Jersey                         1-3215                     22-1024240                        
  (State or Other Jurisdiction of    -Commission File Number    -IRS Employer Identification No.  
  Incorporation)                                                                                  
                                                                                                  
                           One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933                            
                                                                                                                   
                                     (Address of Principal Executive Offices)                                      
                                                                                                                   
                                                    (Zip Code)                                                     
                                                                                                                   
                                Registrant's telephone number, including area code:                                
                                                                                                                   
                                                   732- 524-0400                                                   
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
                                                                                                    
  Title of each class               Trading Symbol(s)    Name of each exchange on which registered  
  Common Stock, Par Value $1.00     JNJ                  New York Stock Exchange                    
  0.250% Notes Due January 2022     JNJ22                New York Stock Exchange                    
  0.650% Notes Due May 2024         JNJ24C               New York Stock Exchange                    
  5.50% Notes Due November 2024     JNJ24BP              New York Stock Exchange                    
  1.150% Notes Due November 2028    JNJ28                New York Stock Exchange                    
  1.650% Notes Due May 2035         JNJ35                New York Stock Exchange                    
                                                                                                    
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) T he 2021 Annual Meeting of Shareholders was held on April 22, 2021.

(b) At the 2021 Annual Meeting of Shareholders, the shareholders:

• elected all 14 Director nominees named in the 2021 Proxy Statement to the Company's Board of Directors;

• approved, on an advisory basis, the executive compensation philosophy, policies and procedures described in the
“Compensation Discussion and Analysis” section of the 2021 proxy statement and the compensation of the Company's
executive officers named in the 2021 Proxy Statement, as disclosed therein;

• ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting
firm for the fiscal year 2021;

• did not approve the shareholder proposal for a report on government financial support and access to COVID-19
vaccines and therapeutics;

• did not approve the shareholder proposal for an independent board chair;

• did not approve the shareholder proposal for a civil rights audit; and

• did not approve the shareholder proposal for executive compensation bonus deferral.

The following are the final voting results for each of the seven items voted on at the meeting.

1. Election of Directors:
                                                                                        
                         Shares For    Shares Against    Shares Abstain      Non-Votes  
  M. C. Beckerle      1,810,423,629        16,477,577         4,324,787    361,631,706  
  D. S. Davis         1,760,086,673        65,980,033         5,159,287    361,631,706  
  I. E. L. Davis      1,788,731,967        37,515,980         4,978,046    361,631,706  
  J. A. Doudna        1,814,385,723        12,552,555         4,287,715    361,631,706  
  A. Gorsky           1,699,594,759       119,253,059        12,378,175    361,631,706  
  M. A. Hewson        1,777,336,871        49,480,838         4,408,284    361,631,706  
  H. Joly             1,775,886,493        50,205,313         5,134,187    361,631,706  
  M. B. McClellan     1,808,590,798        17,138,760         5,496,435    361,631,706  
  A. M. Mulcahy       1,614,611,649       195,380,452        21,233,892    361,631,706  
  C. Prince           1,649,989,314       176,521,719         4,714,960    361,631,706  
  A. E. Washington    1,773,129,639        53,253,564         4,842,790    361,631,706  
  M. A. Weinberger    1,809,184,712        16,475,730         5,565,551    361,631,706  
  N. Y. West          1,817,859,141         8,942,629         4,424,223    361,631,706  
  R. A. Williams      1,749,060,576        77,138,736         5,026,681    361,631,706  
                                                                                        
2. Advisory Vote to Approve Named Executive Officer Compensation:
                            
  For          986,844,148  
  Against      753,486,152  
  Abstain       90,895,693  
  Non-Votes    361,631,706  
                            
3. Ratification of Appointment of PricewaterhouseCoopers LLC as the Independent Registered Public Accounting Firm
for 2021 :
                                   
  For          2,080,036,325       
  Against        108,538,970       
  Abstain          4,282,404       
  Non-Votes                   N/A  
                                   
4. Shareholder Proposal - Report on Government Financial Support and Access to COVID-19 Vaccines and Therapeutics:
                              
  For            573,465,487  
  Against      1,231,071,897  
  Abstain         26,688,609  
  Non-Votes      361,631,706  
                              
5. Shareholder Proposal - Independent Board Chair:
                              
  For            789,938,907  
  Against      1,032,409,877  
  Abstain          8,877,209  
  Non-Votes      361,631,706  
                              
6. Shareholder Proposal - Civil Rights Audit:
                              
  For            611,417,042  
  Against      1,192,232,580  
  Abstain         27,576,371  
  Non-Votes      361,631,706  
                              
7. Shareholder Proposal - Executive Compensation Bonus Deferral
                              
  For            410,065,480  
  Against      1,406,949,986  
  Abstain         14,210,527  
  Non-Votes      361,631,706  
                              
                                                                                                                   
                                                    SIGNATURES                                                     
                                                                                                                   
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
                                                                    
                             Johnson &         (Registrant)         
  Date:    April 26, 2021    Johnson    By:    /s/ Matthew Orlando  
 ────────────────────────────────────────────────────────────────── 
                                               Matthew Orlando      
                                               Secretary            
                                                                    
